In a recent Nikkei feature, IPOX® CEO Josef Schuster provided expert commentary on PayPay's $12.1 billion debut on the U.S. Nasdaq. The Japanese smartphone payment giant, backed by SoftBank, aims to leverage its new capital to build a comprehensive digital financial platform. While acknowledging the fierce competition from established U.S. payment giants, Schuster highlighted a unique opportunity for PayPay to fill a void in the market, despite structural concerns regarding the offering's limited share liquidity.

A recent Reuters article covers the highly anticipated $880 million Nasdaq IPO of SoftBank’s digital payment giant, PayPay. Despite global market volatility, the Japanese app successfully debuted with a $10.7 billion valuation. IPOX® Research Associate Lukas Muehlbauer provided commentary on the offering's strategic pricing and the company's unique market position. Muehlbauer highlighted that we are currently in an IPO "buyers' market" and noted that PayPay's dominant domestic strength insulates it from broader geopolitical and macroeconomic concerns.

Reuters covered the Nasdaq debut of Medtronic's diabetes unit, MiniMed, which opened below its offer price amid heightened market volatility. The $5.35 billion listing highlights ongoing challenges in the new issues market. IPOX® Research Associate Lukas Muehlbauer provided expert commentary on the debut, noting that while the offering "shows that the U.S. IPO market is still open," current economic conditions clearly dictate "that it has become a price-sensitive buyers' market."

A recent Bloomberg article highlights the massive outperformance of European defense and aerospace IPOs, which have averaged 87% gains since 2020. Driven by geopolitical tensions and NATO rearmament, this surge in investor demand is prompting a fresh wave of public listings. IPOX® Research Analyst Lukas Muehlbauer provided expert commentary, explaining that ongoing conflicts have created unprecedented backlogs, making IPOs a practical way for defense firms to raise cash and expand capacity.

Reuters highlights SoftBank-backed PayPay’s upcoming $13.4 billion U.S. IPO, a highly anticipated offering expected to boost a volatile listing market. Discussing current market dynamics, IPOX® CEO Josef Schuster noted robust investor appetite is particularly strong for specialty firms across healthcare and select fintech that are insulated from geopolitical and AI-related risks.

A recent Reuters article highlights Medtronic’s plan to spin off its diabetes unit, MiniMed, targeting a $7.9 billion valuation in its upcoming U.S. IPO. Seeking to raise up to $784 million, the move allows Medtronic to focus on high-margin growth markets. IPOX® Research Associate Lukas Muehlbauer provided expert commentary on the spin-off, noting that while MiniMed offers investors pure-play exposure to diabetes technology as an established business, its recent net losses mean investors will demand a clear path to profitability.

Reuters highlights Generate Biomedicines' upcoming U.S. IPO, targeting a $2.17 billion valuation. As the biotech IPO market resurges, the firm aims to raise $425 million for its AI-driven drug discovery pipeline. IPOX® Research Associate Lukas Muehlbauer provided expert commentary, noting that Generate's institutional backing and pharma partnerships offer significant credibility. However, he emphasized that investors will closely scrutinize the platform's valuation, demanding clear proof of its AI capabilities.

Reuters reports that Wall Street broker Clear Street has withdrawn its U.S. IPO amid market volatility and AI disruption fears. The withdrawal highlights ongoing challenges for fintech firms navigating weak sector sentiment. IPOX® VP Kat Liu provided expert commentary, noting the risks of forcing a poorly received offering. "If demand wasn't there even at a severe discount, pushing through a weakly received deal would have risked the stigma of a 'failed' IPO," Liu explained

A recent Bloomberg article notes that while recent European stock debuts face market pressure, traditional sectors like banking and energy demonstrate strong resilience. Amid a slow market for follow-on offerings, IPOX® Research Associate Lukas Muehlbauer commented on the challenges of underwater stocks.

A recent Reuters article highlights Blackstone-backed Liftoff Mobile's decision to withdraw its U.S. IPO amid a sharp software sector selloff. This sudden delay reflects broader market volatility driven by rapid AI advancements threatening established economic moats. IPOX® Research Associate Lukas Muehlbauer provided expert commentary on the situation, noting that private equity sponsors prefer withdrawing over accepting deeply disappointing valuations. Muehlbauer emphasized that current investor skepticism is a healthy sign of a disciplined market, preventing overheating and benefiting long-term pipeline stability.

ARKO Petroleum’s recent Nasdaq debut, valued at $808 million, saw shares slip 1.4% amid heightened market volatility. IPOX® VP Kat Liu provided expert analysis on the cautious investor sentiment surrounding 2026 listings. "In the current environment, where volatility remains elevated and many IPOs have struggled to hold above their offer price, investors are definitely approaching deals with caution," Liu noted, highlighting the growing scrutiny facing new stocks in today's shifting financial landscape.

A Reuters article details Wall Street broker Clear Street’s decision to slash its IPO fundraising target by 65% amid investor caution. IPOX® Research Associate Lukas Muehlbauer provided expert commentary, noting that recent volatility in AI-driven financial stocks and sharp declines in crypto markets likely dampened sentiment, given Clear Street's exposure to crypto treasury capital raises. The move reflects a broader trend of demanding realistic pricing for new listings.

Agibank slashed its U.S. IPO size by over 50% and lowered its price range following the poor aftermarket performance of rival PicPay. Reuters featured IPOX® Research Associate Lukas Muehlbauer, who analyzed the valuation pressures facing the Brazilian fintech. Muehlbauer noted that while the restructured deal, now consisting solely of primary shares, allows the listing to proceed, it introduces potential stock overhang risks as existing shareholders chose to retain their positions rather than sell at lower valuations.

A recent Bloomberg article highlights the debate over Saudi Arabia’s push to increase retail IPO allocations to 30%. IPOX® Associate Muehlbauer is featured, noting that high retail quotas in a recovering market may force issuers to offer steeper discounts. This post includes Muehlbauer's full commentary to Bloomberg, discussing global parallels with India’s model and the potential for these allocations to serve as "citizen dividends," while cautioning against short-term volatility risks.

Belgium’s Agomab Therapeutics debuted on the Nasdaq with a $716 million valuation, despite shares slipping 8% amid a selective market. While biotech activity is rebounding, investor caution remains high for clinical-stage firms. IPOX® Research Associate Lukas Muehlbauer noted that while the window for drugmakers remains open, it is effectively closed for software firms, highlighting a significant divergence in risk appetite across sectors in the current IPO landscape.

Reuters highlights Forgent Power’s successful $8 billion NYSE debut, underscoring the enduring demand for AI infrastructure. IPOX® Research Associate Lukas Muehlbauer provided expert commentary, noting that the midpoint pricing signals "healthy but disciplined investor demand" amid volatility. He emphasized Forgent’s strategic value as a critical infrastructure provider, offering unique exposure to the AI sector distinct from traditional tech firms, driven by surging data center needs.

Reuters features IPOX® Associate Lukas Muehlbauer’s commentary on York Space Systems’ $4.75 billion NYSE debut. Muehlbauer notes that the successful listing signals a receptive market for defense and space stocks in 2026, setting the stage for the highly anticipated SpaceX IPO. He also analyzes York’s acquisition of ATLAS Space Operations, cautioning that despite the push into software services, the stock will likely remain volatile and sensitive to government spending news in the near term.

Reuters features IPOX® Research Associate Lukas Muehlbauer’s analysis on Eikon Therapeutics' upcoming $908 million IPO. Muehlbauer highlights the premium placed on CEO Roger Perlmutter’s leadership and the company’s Nobel Prize-backed drug discovery platform. He further contrasts Eikon with recent listings like Aktis Oncology, explaining how Eikon aims to overcome historical toxicity challenges in immune-stimulating drugs. This listing signals renewed momentum for the biotech sector following a challenging 2025.

Bloomberg features IPOX® CEO Josef Schuster’s analysis on the "Once Upon a Farm" IPO, co-founded by Jennifer Garner. Discussing the "Hollywood IPO Curse," Schuster warns that celebrity-backed deals historically underperform, citing an "eight out of 11" failure rate. He urges investors to prioritize operational expertise and management resumes over star power. The article underscores the critical importance of evaluating business fundamentals versus celebrity marketing when assessing new public listings.

Reuters reports that Bob's Discount Furniture is targeting a $2.5 billion valuation in its upcoming NYSE IPO. IPOX® VP Kat Liu analyzed the retailer's position regarding trade risks, noting that the company’s shift away from China sourcing helps mitigate specific tariff concerns. However, Liu cautioned that the stock might still experience volatility driven by broader market sentiment regarding freight costs and global trade, rather than direct margin impacts.